ClinicalTrials.gg
CompletedNCT04887532Updated Sep 24, 2021

A Trial of HR19042 Capsule in Healthy Chinese Subjects

A Phase 1 interventional study of HR19042 capsule in Primary IgA Nephropathy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 3 under way, 1 of them phase 3. Glomerulonephritis, IGA · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
11th of 11
12 · median 61
Started
2021
with 1 other
Phase 1
5 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 1, and was the 1st registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

3 of the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 \~ 45 years old, including boundary value;
  2. Female subjects weigh ≥45kg, male subjects weigh ≥50kg, and (BMI) is within the range of 19.0\~26.0kg/m2 (body mass index = weight (kg)/height 2 (m2)), including boundary values;
  3. The subject has no plans to give birth or donate sperm/eggs for at least 3 months from the signing of the form to the end of the study, and voluntarily take effective non-drug measures (including partners) during the trial period;
  4. Before the test, learn more about the nature, significance, possible benefits, possible inconvenience and potential risks of the test. Able to understand the procedures and methods of this research, willing to strictly abide by the clinical trial protocol to complete the trial, and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. People with a known history of drug or food allergies;
  2. Past or current history of any disease that may affect the safety of subjects participating in the trial or the internal process of the research drug, including: digestive system, blood system, circulatory system, urinary system, respiratory system, nervous system, immune system, endocrine system, Those with a clear history of mental disorders and metabolic disorders, or other diseases that are not suitable for participating in clinical trials;
  3. Those who have used drugs that affect the function of liver metabolic enzyme within 30 days before the first administration (such as inducers-enzalutamide, mitotane, carbamazepine, phenytoin, rifampin; inhibitors-clarithromycin, irradian) Traconazole, ketoconazole, ritonavir, telithromycin, etc.), or those who have used within 30 days before administration;
  4. Those who have used any drug within 14 days before the first dose;
  5. Those who have taken a special diet (including grapefruit/grapefruit juice, chocolate, food or beverages containing caffeine) within 48 hours before the first administration, or have consumed excessive amounts of tea, coffee or beverages containing caffeine every day for the past 1 month (Average more than 8 cups per day, 200 mL per cup);
  6. Participate in drug clinical trials and take trial drugs as subjects within 3 months before screening, or plan to participate in other clinical trials during the study period;
  7. Those who donated blood or lost more than 400 mL (excluding menstrual blood loss in women) within 3 months before screening, received blood transfusion or used blood products, or planned to donate blood during the trial period or within 1 month after the end of the trial;
  8. Those who have undergone major surgery within 3 months before screening, or plan to undergo surgery during the study period;
  9. Those who smoked more than 5 cigarettes a day on average in the 3 months before screening, or who did not agree to ban smoking during the trial;
  10. In the 6 months before screening, the average weekly alcohol consumption exceeded 14 units of alcohol (1 unit = 360 mL of beer with 5% alcohol content or 45 mL of spirits with 40% alcohol content or 150 mL of wine with 12% alcohol content), Or those who do not agree to abstain from alcohol during the trial;
  11. The results of laboratory tests (blood routine, urine routine, blood biochemistry, blood coagulation function) are judged by clinicians as abnormal and ;
  12. Those whose 12-lead , physical examination or vital signs examination results are judged by clinicians as abnormal and clinically meaningful;
  13. Immunological examinations ( surface antigen, virus antibody, antibody, Treponema pallidum antibody) are positive;
  14. Those with abnormal chest radiograph (posterior anterior position) and clinical significance;
  15. Women who are pregnant or breastfeeding;
  16. Those who have a positive alcohol breath test;
  17. Those who have a positive urine drug screening;
  18. Those who have a history of drug abuse or drug abuse;
  19. People with a history of difficulty in venous blood collection, intolerance to venipuncture, or a history of fainting needles
  20. Those who have difficulty swallowing, or have special dietary requirements and cannot follow a uniform diet;
  21. The investigator believes that the subject has any other factors that are not suitable for participating in this trial (such as inability to understand the research requirements, poor compliance, infirmity, etc.).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    HR19042 capsule

    Drug: HR19042 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak concentration of drug observed from 0 hour to 24 hours after administration

    Time frame: 0-24 hours

  2. AUC0-t;

    The area under the drug concentration-time curve at the sample collection time t that can be accurately determined from 0 hour to 24 hours after administration

    Time frame: 0-24 hours

  3. AUC0-∞

    The area under the concentration-time curve of drug from 0 hour to infinity after administration

    Time frame: 0 hour to 24 hours

Secondary outcomes

  1. AE

    Adverse event

    Time frame: Screening period to end of follow-up period, approximately 1 month

  2. the change of blood cortisol AUC0-24h from baseline after each cycle of administration

    Time frame: 0-24 hours

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai 200231, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2021, 0 months.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
May 14, 2021
StartActual
Jul 1, 2021
Primary completionActual
Jul 27, 2021
CompletionActual
Jul 27, 2021
Last update
Sep 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04887532
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Jul 1, 2021
Primary completion
Jul 27, 2021
Completion
Jul 27, 2021
Last update
Sep 24, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR19042

Start the discussion